Transaction · 0001704336-26-000005

Cloonan Michael

Cloonan Michael, PRES, CEO, reported a transaction classified as return at Sionna Therapeutics, Inc. involving 436100.000000 shares for an estimated $0.00. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

returnSEC transaction code DPRES, CEO
SIONSionna Therapeutics, Inc.
Trade date
Sep 17, 2026
Filing date
Sep 18, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded436k$0.00 per share
Holdings after0Direct
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

SION price since this filing

Daily closing prices, with the filing date and available return windows
SION · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -12.0%1w ago +0.0%1d ago +0.0%
Returns since7d -22.5%30d -42.4%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
return
Code D
Identifier
0001704336-26-000005
Non-Qualified Stock Option (right to buy)
Transaction date
Sep 17, 2026
Filed Sep 18, 2026, 08:52 PM · 1d delay
Shares
436,100 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
0 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President & CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Re…

  2. F2

    Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, su…

  3. F3

    The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the "Repricing Date"). Unless otherwise provided b…

  4. F4

    Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16…

  5. F5

    This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applica…

Original filing · 0001704336-26-000005
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

SION